OR51E2 and prostate cancer: PSGR/OR51E2 has been shown to play a role in inhibiting proliferation of prostate cancer cells (Neuhaus et al., 2009), a function that is thought to involve activation of TRPV6 (Spehr et al., 2011) and Pyk2 (Wiese et al., 2015).